Zhang Yan-Hua, Su Bo, Sun Pei, Li Ru-Meng, Peng Xiao-Chun, Cai Jun
Department of Oncology, First Affiliated Hospital, Yangtze University, Jingzhou 434023, Hubei Province, China.
Laboratory of Oncology, Center for Molecular Medicine, School of Basic Medicine, Yangtze University, Jingzhou 434023, Hubei Province, China.
World J Clin Cases. 2020 Oct 6;8(19):4380-4387. doi: 10.12998/wjcc.v8.i19.4380.
It is not known whether percutaneous radiofrequency ablation (PRFA) has the same treatment efficacy and fewer complications than laparoscopic resection in patients with small centrally located hepatocellular carcinoma (HCC).
To compare the effectiveness of PRFA with classical laparoscopic resection in patients with small HCC and document the safety parameters.
In this retrospective study, 85 patients treated with hepatic resection (HR) and 90 PRFA-treated patients were enrolled in our hospital from July 2016 to July 2019. Treatment outcomes, including major complications and survival data, were evaluated.
The results showed that minor differences existed in the baseline characteristics between the patients in the two groups. PRFA significantly increased cumulative recurrence-free survival (hazard ratio 1.048, 95%CI: 0.265-3.268) and overall survival (hazard ratio 0.126, 95%CI: 0.025-0.973); PRFA had a lower rate of major complications than HR (7.78% 20.0%, < 0.05), and hospital stay was shorter in the PRFA group than in the HR group (7.8 ± 0.2 d 9.5 ± 0.3 d, < 0.001).
Based on the data obtained, we conclude that PRFA was superior to HR and may reduce complications and hospital stay in patients with small HCC.
对于中心型小肝癌患者，经皮射频消融术（PRFA）的治疗效果是否与腹腔镜切除术相同且并发症更少尚不清楚。
比较PRFA与经典腹腔镜切除术治疗小肝癌患者的有效性，并记录安全性参数。
在这项回顾性研究中，2016年7月至2019年7月期间我院纳入了85例行肝切除术（HR）的患者和90例行PRFA治疗的患者。评估治疗结果，包括主要并发症和生存数据。
结果显示，两组患者的基线特征存在微小差异。PRFA显著提高了累积无复发生存率（风险比1.048，95%置信区间：0.265 - 3.268）和总生存率（风险比0.126，95%置信区间：0.025 - 0.973）；PRFA的主要并发症发生率低于HR（7.78%对20.0%，P<0.05），且PRFA组的住院时间比HR组短（7.8±0.2天对9.5±0.3天，P<0.001）。
基于所获得的数据，我们得出结论，PRFA优于HR，并且可能减少小肝癌患者的并发症和住院时间。
